Patient, physician, and procedural factors influencing the use of defibrillation testing during initial implantable cardioverter defibrillator insertion: Findings from the NCDR®

PACE - Pacing and Clinical Electrophysiology

Volumn 36, Issue 12, 2013, Pages 1522-1531

  Russo, Andrea M ^a   Wang, Yongfei ^b   Al Khatib, Sana M ^c   Curtis, Jeptha P ^b   Lampert, Rachel ^b  

^a Cooper University Hospital ^*  (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

arrhythmia; defibrillation testing; implantable cardioverter defibrillator; registry

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; WARFARIN;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PROCEDURE; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DEATH; DEFIBRILLATION; DEFIBRILLATOR TESTING; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTATION; LENGTH OF STAY; MEDICAL DEVICE COMPLICATION; MEDICAL PRACTICE; PHYSICIAN; PRIMARY PREVENTION; REGISTER; TEACHING HOSPITAL; TREATMENT INDICATION; UNITED STATES;

ARRHYTHMIA; DEFIBRILLATION TESTING; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; REGISTRY;

AGE DISTRIBUTION; AGED; ARRHYTHMIAS, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; EQUIPMENT FAILURE; EQUIPMENT FAILURE ANALYSIS; FEMALE; HEART FAILURE; HUMANS; LENGTH OF STAY; MALE; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; REGISTRIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 84889686156     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/pace.12248     Document Type: Article

References (33)

1. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337: 1576-1583.
2. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21: 2071-2078.
3. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-1940.
4. Moss AJ, Zareba W, Hall J, Klein H, Wilber DJ, Cannom DS, Daubert JP, et al.; the Multi-center Automatic Defibrillator Implantation II Trial Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
5. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G,; the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341: 1882-1890.
6. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, et al. for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-2158.
7. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, et al. for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
8. Hammill SC, Kremers MS, Stevenson LW, Heidenreich PA, Lang CM, Curtis JP, Wang Y, et al. Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. Heart Rhythm 2010; 7: 1340-1345.
9. Reynolds MR, Cohen DJ, Kugelmase AD, Brown PP, Becker ER, Culler SD, Simon AW,. The frequency and incremental cost of major complications among Medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol 2006; 47: 2493-2497.
10. Al-Khatib SM, Greiner MA, Peterson ED, Hernandez AF, Schulman KA, Curtis LH,. Patient and implanting physician factors associated with mortality and complications following implantable cardioverter-defibrillator implantation, 2002-2005. Circ Arrhythm Electrophysiol 2008; 1: 240-249.
11. Wyse DG, Kavanagh KM, Gillis AM, Mitchell LB, Duff HJ, Sheldon RS, Kieser TM, et al. Comparison of biphasic and monophasic shocks for defibrillation using a nonthoracotomy system. Am J Cardiol 1993; 71: 197-202.
12. Neuzner J, Pitschner HF, Huth C, Schlepper M,. Effect of biphasic waveform pulse on endocardial defibrillation efficacy in humans. Pacing Clin Electrophysiol 1994; 17: 207-212.
13. Natale A, Sra J, Krum D, Dhala A, Deshpande S, Jazayeri M, Axtell K, et al. Comparison of biphasic and monophasic pulses: Does the advantage of biphasic shocks depend on the waveshape? Pacing Clin Electrophysiol 1995; 18: 1354-1361.
14. Olsovsky MR, Hodgson DM, Shorofsky SR, Kavesh NG, Gold MR,. Effect of biphasic waveforms on transvenous defibrillation thresholds in patients with coronary artery disease. Am J Cardiol 1997; 80: 1098-1100.
15. Gold MR, Foster AH, Shorofsky SR,. Effects of an active pectoral-pulse generator shell on defibrillation efficacy with a transvenous lead system. Am J Cardiol 1996; 78: 540-543.
16. Bardy GH, Yee R, Jung W,. Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator; Active Can Investigators. J Am Coll Cardiol 1996; 28: 400-410.
17. Bardy GH, Johnson G, Poole JE, Dolack GL, Kudenchuk PJ, Kelso D, Mitchell R, et al. A simplified, single-lead unipolar transvenous cardioversion- defibrillation system. Circulation 1993; 88: 543-547.
18. Strickberger SA, Klein GJ,. Is defibrillation testing required for defibrillator implantation? J Am Coll Cardiol 2004; 44: 88-91.
19. Russo AM, Sauer W, Gerstenfeld EP, Hsia HH, Lin D, Cooper JM, Dixit S, et al. Defibrillation threshold testing: Is it really necessary at the time of implantable cardioverter-defibrillator insertion? Heart Rhythm 2005; 2: 456-461.
20. Brignole M, Raciti G, Bongiorni MG, De Martino G, Favale S, Gasparini M, Luise R, et al. Defibrillation testing at the time of implantation of cardioverter defibrillator in the clinical practice: A nation-wide survey. Europace 2007; 9: 540-543.
21. Birnie D, Tung S, Simpson C, Crystal E, Exner D, Avala Paredes FA, Krahn A, et al. Complications associated with defibrillation threshold testing: The Canadian experience. Heart Rhythm 2008; 5: 387-390.
22. Russo AM, Gerstenfeld EP, Dixit S, Leong-Sit, Hutchinson M, Riley M, Bala R, et al. Changing patterns of defibrillation testing at the time of implantable cardioverter defibrillator insertion over the past 8 years. J Am Coll Cardiol 2009; 53: A134.
23. Day JD, Olshansky B, Moore S, Brown S, Stolen KQ, Lerew DR,; INTRINSIC RV Study Investigators. High defibrillation energy requirements are encountered rarely with modern dual-chamber implantable cardioverter-defibrillator systems. Europace 2008; 10: 347-350.
24. Mainigi SK, Cooper JM, Russo AM, Nayak HM, Lin D, Dixit S, Gerstenfeld EP, et al. Elevated defibrillation thresholds in patients undergoing biventricular defibrillator implantation: Incidence and predictors. Heart Rhythm 2006; 3: 1010-1016.
25. Swerdlow CD, Russo AM, Degroot PJ,. The dilemma of ICD implant testing. Pacing Clin Electrophysiol 2007; 30: 675-700.
26. Pires LA, Johnson KM,. Intraoperative testing of the implantable cardioverter defibrillator: How much is enough? J Cardiovasc Electrophyisol 2006; 17: 140-145.
27. Frame R, Brodman R, Gross J, Hollinger I, Fisher JD, Kim SG, Ferrick K, et al. Initial experience with transvenous implantable cardioverter defibrillator lead systems: Operative morbidity and mortality. Pacing Clin Electrophysiol 1993; 16: 149-152.
28. Shukla HH, Flaker GC, Jayam V, Roberts D,. High defibrillation thresholds in transvenous biphasic implantable defibrillators: Clinical predictors and prognostic implications. Pacing Clin Electrophysiol 2003; 26 (Pt I): 44-48.
29. Blatt JA, Poole JE, Johnson GW, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, et al. No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol 2008; 52: 551-556.
30. Rosenheck S, Sharon Z, Weiss A,. Long-term follow-up of patients with relatively high effective defibrillation threshold during cardioverter defibrillator implantation with endocardial leads. Cardiology 2009; 112: 107-113.
31. Gold MR, Higgins S, Klein R, Gilliam FR, Kopelman H, Hessen S, Payne J, et al. Efficacy and temporal stability of reduced safety margins for ventricular defibrillation: Primary results from the Low Energy Safety Study (LESS). Circulation 2002; 105: 2043-2048.
32. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) Trial results. Circulation 2004; 110: 2591-2596.
33. The Shockless Implant Evaluation (SIMPLE); ClinicalTrials.gov identifier NCT00800384.